Effects of Fenofibrate and Pioglitazone on Bone Health in Ovariectomized Rats
Author Information
Author(s): Stunes Astrid K, Westbroek Irene, Gustafsson Björn I, Fossmark Reidar, Waarsing Jan H, Eriksen Erik F, Petzold Christiane, Reseland Janne E, Syversen Unni
Primary Institution: Norwegian University of Science and Technology, NTNU
Hypothesis
The study investigates the effects of PPARalpha and PPARgamma agonists on bone mineral density and architecture in ovariectomized rats.
Conclusion
Fenofibrate helps maintain bone mass and architecture, while pioglitazone exacerbates bone loss in ovariectomized rats.
Supporting Evidence
- Fenofibrate maintained bone mineral density at levels similar to sham-operated controls.
- Pioglitazone led to lower bone mineral density and impaired bone quality.
- Both fenofibrate and Wyeth 14643 showed positive effects on bone architecture.
- Ovariectomized rats treated with pioglitazone exhibited significant bone loss.
Takeaway
This study shows that fenofibrate is good for bones, while pioglitazone can make bones weaker.
Methodology
Fifty-five female Sprague-Dawley rats were divided into groups and treated with different agents for four months, with bone density and architecture assessed using DXA and microCT.
Limitations
The study was conducted on a specific rat model, which may not fully represent human physiology.
Participant Demographics
Female Sprague-Dawley rats, 12 weeks of age.
Statistical Information
P-Value
p = 0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website